Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars
Executive Summary
FDA is ending one of the landmark drug safety programs from the REMS era, announcing it has released Amgen from its mandatory obligations for the erythropoiesis-stimulating agent (ESA) class. The decision comes just ahead of the likely approval of the first biosimilar application in the class.
You may also be interested in...
US FDA’s REMS Reluctance On Display At Recent Advisory Committees
Drug safety focused meetings would once have been almost certain to focus on mandatory risk management plans as a solution. But FDA not only didn’t propose that approach, it actively discouraged its advisors from considering it.
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.